TherapeuticsMD (TXMD) Cash from Operations Growth (3y) (2013 - 2026)
TherapeuticsMD (TXMD) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 8.25% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 52.97% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 5.90% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 43.42% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -10.08% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -8.76% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 65.60% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | TherapeuticsMD | 23.54 Mn | 14.35 Mn | - | 30.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.64% |
| Mar 31, 2026 | 28.23% |
| Dec 31, 2025 | -76.85% |
| Sep 30, 2025 | -61.65% |
| Jun 30, 2025 | 26.38% |
| Mar 31, 2025 | 26.81% |
| Dec 31, 2024 | -92.92% |
| Sep 30, 2024 | 87.71% |
| Jun 30, 2024 | 27.13% |
| Mar 31, 2024 | 81.86% |
| Dec 31, 2023 | 45.33% |
| Sep 30, 2023 | 43.85% |
| Jun 30, 2023 | 60.72% |
| Mar 31, 2023 | 39.41% |
| Dec 31, 2022 | 37.42% |
| Sep 30, 2022 | 38.83% |
| Jun 30, 2022 | 25.70% |
| Mar 31, 2022 | 22.34% |
| Dec 31, 2021 | 54.75% |
| Sep 30, 2021 | -3.91% |